SciCombinator

Discover the most talked about and latest scientific content & concepts.

HL Kaufman, RHI Andtbacka, FA Collichio, M Wolf, Z Zhao, M Shilkrut, I Puzanov and M Ross
Abstract
Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatment and lasting ≥6 months) have been employed. There has not, however, been validation that DRR correlates with other more traditional endpoints of clinical benefit such as overall survival.
Tweets*
26
Facebook likes*
0
Reddit*
0
News coverage*
63
Blogs*
0
SC clicks
0
Concepts
Immune system, ClinicalTrials.gov, Cancer treatments, The Canon of Medicine, Viruses, Microbiology, Immunotherapy, Oncology
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com